We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma
Read MoreHide Full Article
AbbVie (ABBV - Free Report) announced that it has entered into a global strategic transaction with privately-held Teneobio, Inc. to develop and commercialize the latter’s BCMA-targeting immunotherapeutic candidate, TNB-383B. The pre-clinical candidate, which acts by directing the body’s immune system to kill BCMA expressing tumor cells, will be developed as a potential treatment for multiple myeloma.
Per the terms of the candidate, AbbVie will pay $90 million to Teneobio in upfront payments. Teneobio will remain responsible for developing the candidate in the phase I stage of clinical studies. The deal grants AbbVie right to acquire TeneoOne, Inc., an affiliate of Teneobio, and lead the subsequent stages of clinical development of TNB-383B as well as its commercialization.
Teneobio is expected to initiate phase I studies on TNB-383B in the first of 2019.
AbbVie’s shares have declined 17.6% in the past six months against the industry’s increase of 2.1%.
AbbVie’s commercial portfolio of oncology drugs consists of Imbruvica and Venclexta, which generated billions of dollars in revenues in 2018. The company is focused on expanding the label of these drugs. The company is also co-developing Bristol-Myers’ (BMY - Free Report) myeloma drug, Empliciti.
AbbVie has strengthened its oncology portfolio with the addition of TNB-383B. Successful development of the candidate will help the company to penetrate the lucrative cancer segment. With declining sales of its major revenue generator, Humira in Europe due to generic launch and patent expiry nearing in the United States, development of oncology candidates is becoming a necessity.
We note that TNB-383B works using a newer mechanism, which targets the B-cell of the body’s immune system. Although there are several companies developing similar candidates, these B-cell targeting therapies are in early stages of development.
In December 2018, Amgen (AMGN - Free Report) presented clinical data from its early-stage study on anti-BCMA T cell engager, AMG 420. bluebird bio’s (BLUE - Free Report) CAR-T therapy, bb2121, also uses the anti-BCMA mechanism and is being developed in several studies.
It's hard to believe, even for us at Zacks. But from 2000-2018, while the market gained +4.8% per year, our top stock-picking strategy averaged +54.3% per year.
How has that screen done lately? From 2017-2018, it sextupled the market's +15.8% gain with a soaring +98.3% return.
Image: Bigstock
AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma
AbbVie (ABBV - Free Report) announced that it has entered into a global strategic transaction with privately-held Teneobio, Inc. to develop and commercialize the latter’s BCMA-targeting immunotherapeutic candidate, TNB-383B. The pre-clinical candidate, which acts by directing the body’s immune system to kill BCMA expressing tumor cells, will be developed as a potential treatment for multiple myeloma.
Per the terms of the candidate, AbbVie will pay $90 million to Teneobio in upfront payments. Teneobio will remain responsible for developing the candidate in the phase I stage of clinical studies. The deal grants AbbVie right to acquire TeneoOne, Inc., an affiliate of Teneobio, and lead the subsequent stages of clinical development of TNB-383B as well as its commercialization.
Teneobio is expected to initiate phase I studies on TNB-383B in the first of 2019.
AbbVie’s shares have declined 17.6% in the past six months against the industry’s increase of 2.1%.
AbbVie’s commercial portfolio of oncology drugs consists of Imbruvica and Venclexta, which generated billions of dollars in revenues in 2018. The company is focused on expanding the label of these drugs. The company is also co-developing Bristol-Myers’ (BMY - Free Report) myeloma drug, Empliciti.
AbbVie has strengthened its oncology portfolio with the addition of TNB-383B. Successful development of the candidate will help the company to penetrate the lucrative cancer segment. With declining sales of its major revenue generator, Humira in Europe due to generic launch and patent expiry nearing in the United States, development of oncology candidates is becoming a necessity.
We note that TNB-383B works using a newer mechanism, which targets the B-cell of the body’s immune system. Although there are several companies developing similar candidates, these B-cell targeting therapies are in early stages of development.
In December 2018, Amgen (AMGN - Free Report) presented clinical data from its early-stage study on anti-BCMA T cell engager, AMG 420. bluebird bio’s (BLUE - Free Report) CAR-T therapy, bb2121, also uses the anti-BCMA mechanism and is being developed in several studies.
AbbVie Inc. Price
AbbVie Inc. Price | AbbVie Inc. Quote
Zacks Rank
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Best Stock-Picking Strategy
It's hard to believe, even for us at Zacks. But from 2000-2018, while the market gained +4.8% per year, our top stock-picking strategy averaged +54.3% per year.
How has that screen done lately? From 2017-2018, it sextupled the market's +15.8% gain with a soaring +98.3% return.
Free – See the Stocks It Turned Up for Today >>